Search

News Desirable Side Effects of Antidiabetics

The days when diabetology was a field solely focused on normalizing blood sugar levels are long gone. Today, the approach in diabetology increasingly prioritizes influencing the patient's overall life prognosis, particularly reducing cardiovascular risk. What can be the desirable side effects of the main groups of antidiabetics that are not related to merely lowering glucose levels?

Source: Diabetes 6. 11. 2020

News Diosmin –⁠ Still an Important Modality in the Treatment of Venous Insufficiency

Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately, it remains without causal treatment. In the recommended therapeutic procedures, especially in the initial stages, compression treatment supplemented with pharmacotherapy plays a key role. This includes the administration of medicinal products containing micronized diosmin. The following text summarizes basic findings about its properties that predispose it to clinical use.

Source: Venous Insufficiency 3. 1. 2020

News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis

Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.

Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?

Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.

Source: Arthritis 9. 7. 2020

News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?

In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.

Source: Arthritis 21. 4. 2020

News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice

At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.

Source: Intestinal Inflammations 20. 9. 2023

News OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?

How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.

Source: Chronic Lymphocytic Leukemia 19. 6. 2024

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.

Source: Thromboprophylaxis 28. 11. 2023

News Safety of Metamizole in Adult Patients –⁠ Meta-analysis of 79 Studies

Metamizole is a non-opioid analgesic with antipyretic and spasmolytic effects that has been used for over 100 years. It is approved for the treatment of children and adults in various dosage forms. German authors conducted a systematic literature review and meta-analysis of clinical studies to evaluate its safety compared to placebo and other analgesics in adult patients.

Source: Analgesia 30. 5. 2024

News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function -⁠ Findings from a Recent Meta-analysis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.

Source: Heart Failure 3. 11. 2022

News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice

Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?

Source: Cough Therapy 15. 2. 2022

News Romiplostim in Newly Diagnosed or Persistent ITP

Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.

Source: Immune Thrombocytopenia 21. 2. 2023

News Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Antibodies against the programmed cell death protein 1 (PD-1) improve the survival of patients with advanced non-small cell lung cancer (NSCLC). However, their use has not yet been tested in patients with resectable NSCLC. In 2018, the New England Journal of Medicine published the results of a pilot study of neoadjuvant therapy with nivolumab in patients with resectable NSCLC. Based on the promising results of this study, the investigative team subsequently decided to also test a combination of nivolumab and ipilimumab.

Source: Immunotherapy in Oncology 6. 11. 2020

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.

Source: Oncological Treatment 22. 11. 2021

News Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients

Energy intake and the composition of individual macronutrients in patients in intensive care units (ICUs) can influence treatment outcomes in terms of the incidence of complications, duration of mechanical ventilation, or mortality.

Source: Parenteral Nutrition 14. 11. 2022